BMO Capital Markets restated their outperform rating on shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) in a research report released on Wednesday, March 14th. They currently have a $18.00 price target on the biotechnology company’s stock.
Separately, Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a buy rating to a hold rating in a report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $11.83.
AGLE stock traded down $0.87 during midday trading on Wednesday, hitting $8.92. The stock had a trading volume of 71,629 shares, compared to its average volume of 97,920. The firm has a market cap of $163.65, a price-to-earnings ratio of -4.96 and a beta of -0.16. Aeglea Bio Therapeutics has a 1-year low of $2.81 and a 1-year high of $11.35.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its earnings results on Tuesday, March 13th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter. The firm had revenue of $1.48 million during the quarter. Aeglea Bio Therapeutics had a negative net margin of 523.37% and a negative return on equity of 48.29%. equities analysts anticipate that Aeglea Bio Therapeutics will post -1.93 earnings per share for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC raised its holdings in shares of Aeglea Bio Therapeutics by 0.6% in the 4th quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after acquiring an additional 8,372 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Aeglea Bio Therapeutics by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after acquiring an additional 12,966 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Aeglea Bio Therapeutics by 150.8% in the 4th quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 19,300 shares during the last quarter. Institutional investors own 47.43% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/aeglea-bio-therapeutics-agle-stock-rating-reaffirmed-by-bmo-capital-markets.html.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.